danoprevir
Danoprevir (INN) is an orally available 15-membered macrocyclic peptidomimetic inhibitor of NS3/4A HCV protease. It contains acylsulfonamide, fluoroisoindole and tert-butyl carbamate moieties. Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC50 = 0.2–0.4 nM; replicon GT1b, EC50 = 1.6 nM). Danoprevir has been evaluated in an open-label, single arm clinical trial in combination with ritonavir for treating COVID-19 and favourably compared to lopinavir/ritonavir in a second trial. — Wikipedia
Clinical trial activity
34 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2008 (NCT00801255)
Timeline
Indications
Approved for
Mechanism of action
Hepatitis C virus serine protease, NS3/NS4A antagonist
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
SMILES
CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O- Mol. weight
- 731.84 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL258734 ↗
- WikipediaDanoprevir ↗
- ChEMBLCHEMBL2311191 ↗
Also known as
- danoprevir
- danoprevir
- danoprevir
- danoprevir
- danoprevir
- itmn191
- itmn 191
- itmn-191
- r 7227
- r-7227
- r7227 cpd
- rg7227
- rg7227
- rg 7227
- rg-7227
- ro5190591
- ro5190591
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04345276 | Phase 4 | Mar 18, 2020 | Ascletis Pharmaceuticals Co., Ltd., Wuhan Huoshenshan Hospital |
| NCT04291729 | Phase 4 | Feb 17, 2020 | Ascletis Pharmaceuticals Co., Ltd., Nanchang University |
| NCT03288636 | Phase 1 | Aug 8, 2017 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03362814 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2017 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020134 | Phase 1 | Jul 1, 2016 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020082 | Phase 3 | Jun 1, 2016 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020004 | Phase 2 | Jan 1, 2016 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03019991 | Phase 1 | Oct 1, 2015 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT03020095 | Phase 2 | Aug 1, 2015 | Ascletis Pharmaceuticals Co., Ltd. |
| NCT01749150 | Phase 2 | Apr 1, 2013 | Roche |
| NCT01714154 | Phase 1 | Nov 1, 2012 | Roche |
| NCT01579019 | Phase 2 | Jul 1, 2012 | Roche |
| NCT01654211 | Phase 1 | Jul 1, 2012 | Roche |
| NCT01628094 | Phase 2 | Jun 1, 2012 | Roche |
| NCT01592305 | Phase 1 | May 1, 2012 | Roche |
| NCT01592318 | Phase 1 | May 1, 2012 | Roche |
| NCT01483742 | Phase 2 | Apr 1, 2012 | Roche |
| NCT01588002 | Phase 1 | Apr 1, 2012 | Roche |
| NCT01519336 | Phase 1 | Feb 1, 2012 | Roche |
| NCT01531647 | Phase 1 | Jan 1, 2012 | Roche |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 25 | 25 | 2 | 2008 |
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 9 | 7 | 4 | 2015 |
| Nanchang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Wuhan Huoshenshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |